Revvity, Inc. (RVTY) rises on Q1 beat and deeper margin read
May 5, 202610 min read
Key Takeaway
Revvity, Inc. (RVTY) beat first-quarter expectations with adjusted EPS of $1.06 and revenue of $711.1 million, while adjusted operating margin improved to 23.6%. Investors looked past the lower full-year EPS guide because management tied the reset to a planned China immunodiagnostics divestiture, which should improve organic growth and margins on a pro forma basis.
Revvity, Inc. (RVTY) rises after a clean Q1 beat, with adjusted EPS of $1.06 topping the $1.02 consensus and revenue of $711.1M edging past the $704.2M estimate. The market looked through a lower full-year EPS range because the reset was tied to a strategic exit from China immunodiagnostics, not a broad operating stumble.
Key Takeaways
Revvity, Inc. (RVTY) reported adjusted EPS of $1.06 versus $1.02 expected, while revenue came in at $711.1M versus $704.2M expected.
The standout operating detail was reproductive health in Diagnostics, which grew in the low double digits organically in Q1.
Total company organic growth was 3%, and adjusted operating margin reached 23.6%, above the 23% outlook discussed by management.
Management lowered FY2026 adjusted EPS guidance to $5.20 to $5.30 from $5.35 to $5.45, while framing the change around the planned divestiture of China immunodiagnostics, a business that represented about 6% of FY2025 revenue.
CEO Prahlad Singh called the China exit a "transformative strategic decision" and said it should improve 2026 organic growth by about 100 bps and operating margin by about 30 bps on a pro forma basis.
Analyst reaction was mixed but not hostile: the Street focused on the guide cut, while the broader analyst consensus remained Buy, with 15 Buy ratings and 14 Hold ratings.
Financial Performance Breakdown
The headline for RVTY earnings was straightforward. Revvity delivered a modest beat on both profit and revenue, then paired it with a strategic portfolio move that changes how investors should read the rest of 2026.
Adjusted EPS landed at $1.06, ahead of the $1.02 consensus. Revenue was $711.1M, above the $704.2M estimate. That combination matters because Revvity has now beaten EPS estimates in each of its last five reported quarters. The recent string includes $1.70 versus $1.57 in the prior quarter, $1.18 versus $1.14 in each of the two quarters before that, and $1.01 versus $0.96 a year ago.
From a historical lens, the quarter was solid but not explosive. Quarterly revenue was below the $770M posted in the prior quarter, yet above the $660M recorded in the year-ago comparable quarter. Net income was $40M, matching the level posted in the quarter ended March 30, 2025, but below the $100M recorded in the quarter ended Dec. 28, 2025. That gap helps explain why investors focused more on margin structure and guidance quality than on the headline beat alone.
Margins were one of the cleaner positives in the quarter. CEO Prahlad Singh said adjusted operating margin reached 23.6%, above the 23% outlook. In plain English, execution was better than expected even before the company gets the full benefit of its cost actions and portfolio cleanup.
Our adjusted operating margins came in at 23.6%, which was above our 23% outlook. — Prahlad Singh, President and CEO
Segment detail was more directional than fully broken out for the quarter, but the annual segment mix still gives a useful frame. For full-year 2025, Diagnostics generated $1.4249B and Life Sciences generated $1.4311B. A year earlier, Diagnostics was $1.5009B and Life Sciences was $1.2541B. That tells a clear story: Life Sciences has been the stronger growth engine, while Diagnostics has faced more pressure, especially in China immunodiagnostics.
Within Q1, the strongest callout came from Diagnostics. Singh said reproductive health grew in the low double digits organically, helped by newborn screening and a better-than-expected contribution from the Genomics England contract. By contrast, immunodiagnostics in China remained weak, exactly the business Revvity now plans to divest.
Life Sciences also showed encouraging signs. Singh said the pharma and biotech spending environment improved modestly, producing positive low single-digit organic growth from those customers. He also said academic customers delivered mid-single-digit growth overall, with U.S. academic growth turning positive for the first time since Q2 2023. That is not a full recovery, but it is better footing than the sector had been showing.
The strategic wrinkle is what matters most for Revvity, Inc. earnings analysis. The company plans to divest its immunodiagnostics business in China, which represented about 6% of total company revenue last year. On a pro forma basis, management said excluding that business would have lifted Q1 organic growth to 6% and adjusted operating margin to 24%. That is a sharper business profile, even if the near-term EPS math moves lower.
Market Reaction and Analyst Response
The stock reaction says investors liked the quality of the quarter more than they feared the guidance reset. RVTY rises 6.73% in the regular session to $92.33, with volume of 1,419,846 shares versus an average of 1,129,331. That is a meaningful move on above-average trading activity.
The first reaction was positive as well. Investing.com reported the stock was up 2.7% in premarket trading to $88.80 after the Q1 2026 results. The stronger regular-session gain implies buyers got more comfortable as the strategic logic behind the China exit sank in.
Still, the Street did not get everything it wanted. Management cut FY2026 adjusted EPS guidance to $5.20 to $5.30 from $5.35 to $5.45. That kept analysts focused on the lower earnings base, even though the quarter itself beat and the portfolio move was framed as margin-accretive over time.
Recent analyst actions show that tension. Baird maintained Outperform on May 4 and set a $125 price target, down from $129. Barclays downgraded RVTY to Equal-Weight on April 14 and cut its target to $95 from $118. Goldman Sachs kept a Neutral rating on April 14 and lowered its target to $95 from $110. J.P. Morgan maintained Neutral on March 31 and cut its target to $96 from $105.
There were also more constructive moves earlier in the year. Jefferies maintained Hold on Feb. 3 and raised its target to $105 from $100. TD Cowen maintained Buy and lifted its target to $124 from $120. Evercore ISI maintained Outperform and raised its target to $118 from $112.
The broader setup remains balanced. Analyst consensus stands at Buy, with 15 Buy ratings and 14 Hold ratings. That split fits the current RVTY earnings narrative almost perfectly. The business is executing, but the Street wants proof that the cleaner portfolio and software-led growth story can offset the lower headline earnings guide.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Prahlad Singh set the tone by arguing that Revvity is trading short-term complexity for a stronger long-term model. His central point was that China immunodiagnostics had become a low-growth, lower-margin business that absorbed too much capital and management attention.
Following an extensive review, we have decided to divest our immunodiagnostics business in China, which represented approximately 6% of total company revenue last year. — Prahlad Singh, President and CEO
That quote matters because it reframes the guide cut. This was not management blinking on demand across the whole company. This was management choosing to remove a structurally weaker business. Singh went further and said the exit should improve 2026 total company organic growth by about 100 bps and operating margins by about 30 bps. For investors, that is the real strategic trade: lower near-term EPS, cleaner growth profile.
Singh also leaned hard into AI as a growth narrative for the Life Sciences and software portfolio. He described Revvity as a supplier of the physical validation tools needed after AI generates new drug hypotheses. It is an ambitious framing, but it was tied to concrete product launches such as Xynthetica, BioDesign, and the planned LabGistics rollout later this year.
Every AI-generated discovery will still require physical validation through wet lab experimentation. — Prahlad Singh, President and CEO
That is classic executive language with a practical core. The plain-English version is simple: if AI helps customers design more compounds, Revvity wants to sell more reagents, instruments, and software to test them in the lab.
On the financial side, CFO Max Krakowiak provided the harder numbers. Management's updated pro forma 2026 guidance now excludes the China immunodiagnostics business and calls for 3% to 4% organic growth, adjusted operating margin of 28.4%, and adjusted EPS of $5.20 to $5.30.
As it pertains to our updated pro forma guidance for 2026, which now excludes the immunodiagnostics business in China, we are now looking for organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30. — Max Krakowiak, SVP and CFO
That quote is the financial spine of the quarter. It tells investors that Revvity is asking to be judged on a pro forma business that is more focused and, over time, more profitable.
This move will result in a more focused business with cleaner financial metrics that better reflects our core growth drivers. — Max Krakowiak, SVP and CFO
Analyst Q&A Highlights
The most revealing exchanges in the RVTY earnings call centered on three issues: the real cost of exiting China immunodiagnostics, the health of end-market demand, and whether AI is becoming a commercial driver or just a polished slide deck.
First, analysts pressed management on why a business that was only about 6% of revenue had such an outsized effect on the narrative. Singh's answer was blunt. China diagnostics faced policy-driven pressure on both demand and pricing, and keeping the business competitive would require local manufacturing, supply chain, and regulatory investment. Management chose not to throw good capital after bad conditions. That response was revealing because it showed Revvity is prioritizing return on invested capital over geographic completeness.
Second, analysts pushed on whether pharma, biotech, and academic demand had truly improved or had just stopped getting worse. Singh defended the trend carefully. He said pharma and biotech posted positive low single-digit organic growth, the best year-over-year growth for reagents and instrument sales to that customer group since the first half of 2023. He also noted mid-single-digit academic growth overall and positive U.S. academic growth for the first time since Q2 2023. That is not a victory lap, but it is a measurable shift in direction.
We saw a modestly improved pharma and biotech spending environment in the first quarter. — Prahlad Singh, President and CEO
Third, the AI discussion surfaced as more than branding. Analysts wanted to know whether the company was talking about a distant theme or a nearer commercial opportunity. Singh's response tied AI demand to high-content screening, software launches, and instrument demand linked to GLP-1 research, organ-on-chip work, and data generation for AI model training. In other words, management argued that AI is already influencing buying behavior in selected product lines.
The Q&A tone also showed discipline from finance. Krakowiak's guidance framed the first half as lighter and the second half as stronger as operational efficiency actions roll through. That matters because it keeps the burden of proof on execution, where investors can actually score the company quarter by quarter, rather than on abstract strategy.
Bottom Line
Revvity, Inc. (RVTY) delivered the kind of quarter that usually earns investor patience: a beat on EPS and revenue, better-than-expected margin performance, and a strategic move aimed at improving the shape of the business. The guide cut will keep debate alive, but the market reaction shows investors saw a reset with intent, not a crack in the core story.
For now, the RVTY earnings setup is clear. If Revvity converts its cleaner portfolio, stronger Life Sciences momentum, and margin plan into steady second-half execution, the stock has room to close the gap between a $92.33 share price and still-constructive Wall Street targets.
Yes. Revvity reported adjusted EPS of $1.06 versus the $1.02 consensus and revenue of $711.1 million versus the $704.2 million estimate. It marked the company's fifth straight quarter of beating EPS expectations.
+Why did Revvity lower full-year EPS guidance after a strong quarter?
Management cut FY2026 adjusted EPS guidance to $5.20 to $5.30 from $5.35 to $5.45 because of the planned divestiture of its China immunodiagnostics business. The company said the exit is strategic, not a sign of broad operating weakness.
+What was Revvity's adjusted operating margin in Q1?
Revvity said adjusted operating margin reached 23.6% in Q1, above the 23% outlook management had discussed. On a pro forma basis excluding the China immunodiagnostics business, management said margin would have been 24%.
+How did Revvity's stock react to the Q1 results?
RVTY rose 6.73% in the regular session to $92.33 on above-average volume of 1,419,846 shares. The market focused on the earnings beat, margin strength, and the strategic rationale behind the guidance reset.
Want the full picture on RVTY?
Read the analyst-grade research report — charts, grades, and price targets.
